2Slowey MJ. Polycystic ovary syndrome: new perspective on an old problem[ J]. South Med J, 2001,94 (2) : 190 -196.
3Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS) :the Amsterdam ESHRE/ASRM -Sponsored 3rd PCOS Consensus Workshop Group [J]. Fertil Steril, 2012, 97 ( 1 ) : 28 -38.
4Gambineri A, Pelusi C, Vicennati V, et al. Ohesity and the polycystic ovary syndrome [ J]. lnt J Obes Relat Metab Disord, 2002, 26(7) : 883 - 896.
5Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome[ J ]. B JOG, 2006, 113 (10): 1148-1159.
6Pasquali R, Gambineri A, Cavazza C, et al. Heterogeneity in the responsiveness to long - term lifestyle intervention and predictability in obese women with polycystic ovary syndrome [ J ]. Eur J Endocrinol, 2011, 164 ( 1 ) : 53 -60.
7Kiddy DS, Hamilton -Fairley D, Bush A, et al. hnprovement in endocrine and ovarian function during dietary treatment of obese women with polycystie ovary syndrome[ J]. Clin Endocrinol (Oxf) . 1992, 36 (1): 105-111.
8Golland IM, Elstein ME. Results of an open one - year study with Diane- 35 in women with polycystic ovarian syndrome[ J ]. Ann N Y Acad Sci, 1993, 687 : 263 - 271.
9Sahin Y, Dilber S, Kele tinmr F. Comparison of diane 35 and diane 35 plus finasteride in the treatment of hirsutism [ J]. Fertil Steril,2001, 75 (3) : 496 -500.
10vanWaygen RG, van den Ende A. Experience in the long - term treatment of patients with hirsutism and/or ache with cyproterone acetate - containing preparations : Efficacy, metabolic and endocrine effects [J]. Exp Clin Endocrinol Diabetes, 1995, 103 (4) : 241 -251.
